Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies - Quiz - MDSpire

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

  • By

  • Elvira Umyarova

  • John Sharp

  • Charles Pei

  • William Pellegrino

  • Qiuhong Zhao

  • Nathan Denlinger

  • Timothy Voorhees

  • Marcos De Lima

  • Narendranath Epperla

  • March 12, 2026

  • 0 min

Share

Original Source(s)

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

  • by Elvira Umyarova, John Sharp, Charles Pei, William Pellegrino, Qiuhong Zhao, Nathan Denlinger, Timothy Voorhees, Marcos De Lima, Narendranath Epperla

  • March 12, 2026

Related Content

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders